Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Markus Ketteler(Robert Bosch Hospital), Mary B. Leonard(Palo Alto University), Marc Vervloet(Radboud University Nijmegen), Nigel D. Toussaint(The Royal Melbourne Hospital), Geoffrey A. Block(Renal Associates P. A.), Sharon M. Moe(Indiana University School of Medicine), Pieter Evenepoel(KU Leuven), Linda McCann, Masafumi Fukagawa(FIND), Rukshana Shroff(Great Ormond Street Hospital), Charles A. Herzog(Hennepin Healthcare Research Institute), Marcello Tonelli(University of Calgary)
Cited by 998
Related Papers
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
|Journal of the American Society of Nephrology|2004|2.7k
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
|New England Journal of Medicine|2004|1.1k